drugset / Trial / NCT06725758
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NaSequentialOpen-labelTreatment
Summary
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Timeline
- Start
- 2023-10-26
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ODM-212 | Unknown | 5 mg | — |
| Subject | ODM-212 | Unknown | 40 mg | — |